{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:54:06Z","timestamp":1769500446783,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA014089"],"award-info":[{"award-number":["P30CA014089"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11060-018-2791-y","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T08:09:53Z","timestamp":1518163793000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors"],"prefix":"10.1007","volume":"138","author":[{"given":"Nathan J.","family":"Robison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kee Kiat","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian P.","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jemily","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Sheard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley S.","family":"Margol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Rushing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Finlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Sposto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Dhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"2791_CR1","doi-asserted-by":"publisher","first-page":"v1-v75","DOI":"10.1093\/neuonc\/now207","volume":"18","author":"QT Ostrom","year":"2016","unstructured":"Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009\u20132013. Neuro Oncol 18:v1-v75. \n                    https:\/\/doi.org\/10.1093\/neuonc\/now207","journal-title":"Neuro Oncol"},{"key":"2791_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/MPH.0000000000000551","volume":"38","author":"J Glod","year":"2016","unstructured":"Glod J, Rahme GJ, Kaur H, E HR, Hwang EI, Israel MA (2016) Pediatric brain tumors: current knowledge and therapeutic opportunities. J Pediatr Hematol Oncol 38:249\u2013260. \n                    https:\/\/doi.org\/10.1097\/MPH.0000000000000551","journal-title":"J Pediatr Hematol Oncol"},{"key":"2791_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/1078-0432.CCR-07-1562","volume":"14","author":"JA Blansfield","year":"2008","unstructured":"Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14:270\u2013280. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1562","journal-title":"Clin Cancer Res"},{"key":"2791_CR4","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1158\/0008-5472.CAN-13-0661","volume":"73","author":"H Fang","year":"2013","unstructured":"Fang H, Declerck YA (2013) Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 73:4965\u20134977. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0661","journal-title":"Cancer Res"},{"key":"2791_CR5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","volume":"87","author":"K Dredge","year":"2002","unstructured":"Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166\u20131172. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6600607","journal-title":"Br J Cancer"},{"key":"2791_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","volume":"77","author":"L Lu","year":"2009","unstructured":"Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78\u201386. \n                    https:\/\/doi.org\/10.1016\/j.mvr.2008.08.003","journal-title":"Microvasc Res"},{"key":"2791_CR7","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O\u2019Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878\u20131886","journal-title":"Cancer Res"},{"key":"2791_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045\u20131047. \n                    https:\/\/doi.org\/10.1172\/JCI9872","journal-title":"J Clin Invest"},{"key":"2791_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1373\/clinchem.2012.185363","volume":"59","author":"NE Sounni","year":"2013","unstructured":"Sounni NE, Noel A (2013) Targeting the tumor microenvironment for cancer therapy. Clin Chem 59:85\u201393. \n                    https:\/\/doi.org\/10.1373\/clinchem.2012.185363","journal-title":"Clin Chem"},{"key":"2791_CR10","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516\u20131525. \n                    https:\/\/doi.org\/10.1200\/JCO.1999.17.5.1516","journal-title":"J Clin Oncol"},{"key":"2791_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2478\/raon-2014-0021","volume":"49","author":"T Mesti","year":"2015","unstructured":"Mesti T, Moltara ME, Boc M, Rebersek M, Ocvirk J (2015) Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiol Oncol 49:80\u201385. \n                    https:\/\/doi.org\/10.2478\/raon-2014-0021","journal-title":"Radiol Oncol"},{"key":"2791_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000336483","volume":"82","author":"D Zapletalova","year":"2012","unstructured":"Zapletalova D, Andre N, Deak L, Kyr M, Bajciova V, Mudry P, Dubska L, Demlova R, Pavelka Z, Zitterbart K, Skotakova J, Husek K, Martincekova A, Mazanek P, Kepak T, Doubek M, Kutnikova L, Valik D, Sterba J (2012) Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology 82:249\u2013260. \n                    https:\/\/doi.org\/10.1159\/000336483","journal-title":"Oncology"},{"key":"2791_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/pbc.24006","volume":"59","author":"A Peyrl","year":"2012","unstructured":"Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T, Dieckmann K, Schmook MT, Haberler C, Leiss U, Slavc I (2012) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 59:511\u2013517. \n                    https:\/\/doi.org\/10.1002\/pbc.24006","journal-title":"Pediatr Blood Cancer"},{"key":"2791_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","volume":"29","author":"R Aplenc","year":"2011","unstructured":"Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Adamson PC (2011) Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children\u2019s oncology group phase I consortium. J Clin Oncol 29:839\u2013844. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.30.7231","journal-title":"J Clin Oncol"},{"key":"2791_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2010.08.014","volume":"298","author":"MS Ahluwalia","year":"2010","unstructured":"Ahluwalia MS, de Groot J, Liu WM, Gladson CL (2010) Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett 298:139\u2013149. \n                    https:\/\/doi.org\/10.1016\/j.canlet.2010.08.014","journal-title":"Cancer Lett"},{"key":"2791_CR16","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1021\/ja208518u","volume":"134","author":"H Shi","year":"2012","unstructured":"Shi H, Zhang CJ, Chen GY, Yao SQ (2012) Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. J Am Chem Soc 134:3001\u20133014. \n                    https:\/\/doi.org\/10.1021\/ja208518u","journal-title":"J Am Chem Soc"},{"key":"2791_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","volume":"144","author":"F Fei","year":"2009","unstructured":"Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Gotz M, Dohner H, Bunjes D, Schmitt M (2009) Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. Br J Haematol 144:195\u2013205. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07433.x","journal-title":"Br J Haematol"},{"key":"2791_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/2326-6066.CIR-16-0061-T","volume":"5","author":"C Hekim","year":"2017","unstructured":"Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vaha-Koskela M, Savola P, Tahtinen S, Saikko L, Hemminki A, Kovanen PE, Porkka K, Lee FY, Mustjoki S (2017) Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models. Cancer Immunol Res 5:157\u2013169. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0061-T","journal-title":"Cancer Immunol Res"},{"key":"2791_CR19","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL, Investigators IFM (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782\u20131791. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1114138","journal-title":"N Engl J Med"},{"key":"2791_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1200\/JCO.2010.30.8387","volume":"29","author":"SL Berg","year":"2011","unstructured":"Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, Chen N, Adamson PC, Blaney SM (2011) Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed\/refractory solid tumors or myelodysplastic syndrome: a Children\u2019s Oncology Group Phase I Consortium report. J Clin Oncol 29:316\u2013323. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.30.8387","journal-title":"J Clin Oncol"},{"key":"2791_CR21","doi-asserted-by":"publisher","first-page":"24031","DOI":"10.18632\/oncotarget.15234","volume":"8","author":"M Giuliani","year":"2017","unstructured":"Giuliani M, Janji B, Berchem G (2017) Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget 8:24031\u201324044. \n                    https:\/\/doi.org\/10.18632\/oncotarget.15234","journal-title":"Oncotarget"},{"key":"2791_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","volume":"23","author":"ES Newlands","year":"1997","unstructured":"Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35\u201361","journal-title":"Cancer Treat Rev"},{"key":"2791_CR23","first-page":"33","volume":"16","author":"JT Kim","year":"2006","unstructured":"Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16:33\u201339","journal-title":"Oncol Rep"},{"key":"2791_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1186\/s12885-016-2945-2","volume":"16","author":"ET Wong","year":"2016","unstructured":"Wong ET, Timmons J, Callahan A, O\u2019Loughlin L, Giarusso B, Alsop DC (2016) Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. BMC Cancer 16:914. \n                    https:\/\/doi.org\/10.1186\/s12885-016-2945-2","journal-title":"BMC Cancer"},{"key":"2791_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1158\/1535-7163.MCT-08-0669","volume":"8","author":"V Milano","year":"2009","unstructured":"Milano V, Piao Y, LaFortune T, de Groot J (2009) Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther 8:394\u2013406. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0669","journal-title":"Mol Cancer Ther"},{"key":"2791_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3109\/10428194.2013.794270","volume":"55","author":"I Jungkunz-Stier","year":"2014","unstructured":"Jungkunz-Stier I, Zekl M, Stuhmer T, Einsele H, Seggewiss-Bernhardt R (2014) Modulation of natural killer cell effector functions through lenalidomide\/dasatinib and their combined effects against multiple myeloma cells. Leuk Lymphoma 55:168\u2013176. \n                    https:\/\/doi.org\/10.3109\/10428194.2013.794270","journal-title":"Leuk Lymphoma"},{"key":"2791_CR27","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood.V114.22.1876.1876","volume":"114","author":"T Facon","year":"2009","unstructured":"Facon T, Leleu X, Stewart AK, Spencer A, Rowlings P, Hulin C, Attal M, Garzon F, Bleickardt E, Gialelis K, Tuozzoli D, Derreumaux D, Sonneveld P (2009) Dasatinib in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: preliminary results of a phase I study. Blood 114:1876\u20131876","journal-title":"Blood"},{"key":"2791_CR28","doi-asserted-by":"publisher","first-page":"e2017040","DOI":"10.4084\/mjhid.2017.040","volume":"9","author":"E Cencini","year":"2017","unstructured":"Cencini E, Fabbri A, Arrigucci U, Cerase A, Bocchia M (2017) Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma. Mediterr J Hematol Infect Dis 9:e2017040. \n                    https:\/\/doi.org\/10.4084\/MJHID.2017.040","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2791_CR29","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","volume":"33","author":"NN Laack","year":"2015","unstructured":"Laack NN, Galanis E, Anderson SK, Leinweber C, Buckner JC, Giannini C, Geoffroy FJ, Johnson DR, Lesser GJ, Jaeckle KA, Sarkaria JN (2015) Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance). J Clin Oncol 33:2013\u20132013. \n                    https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.2013","journal-title":"J Clin Oncol"},{"key":"2791_CR30","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708\u2013720. \n                    https:\/\/doi.org\/10.1093\/jnci\/djp079","journal-title":"J Natl Cancer Inst"},{"key":"2791_CR31","first-page":"396","volume":"10","author":"LABRF Trissel","year":"2006","unstructured":"Trissel LABRF., Zhang YB, Koontz SEPB. (2006) Temozolomide stability in extemporaneously compounded oral suspensions. Int J Pharm Compd 10:396\u2013399","journal-title":"Int J Pharm Compd"},{"key":"2791_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/neuonc\/noq205","volume":"13","author":"KJ Cohen","year":"2011","unstructured":"Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s Oncology Group. Neuro Oncol 13:410\u2013416. \n                    https:\/\/doi.org\/10.1093\/neuonc\/noq205","journal-title":"Neuro Oncol"},{"key":"2791_CR33","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","volume":"27","author":"JF Apperley","year":"2009","unstructured":"Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM (2009) Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 27:3472\u20133479. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.14.3339","journal-title":"J Clin Oncol"},{"key":"2791_CR34","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cncr.25035","volume":"116","author":"B Neyns","year":"2010","unstructured":"Neyns B, Tosoni A, Hwu WJ, Reardon DA (2010) Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 116:2868\u20132877. \n                    https:\/\/doi.org\/10.1002\/cncr.25035","journal-title":"Cancer"},{"key":"2791_CR35","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","volume":"28","author":"JR Perry","year":"2010","unstructured":"Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051\u20132057. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.26.5520","journal-title":"J Clin Oncol"},{"key":"2791_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/neuonc\/nos295","volume":"15","author":"A Omuro","year":"2013","unstructured":"Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15:242\u2013250. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nos295","journal-title":"Neuro Oncol"},{"key":"2791_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/neuonc\/noq204","volume":"13","author":"CE Fadul","year":"2011","unstructured":"Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS (2011) Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 13:393\u2013400. \n                    https:\/\/doi.org\/10.1093\/neuonc\/noq204","journal-title":"Neuro Oncol"},{"key":"2791_CR38","doi-asserted-by":"publisher","first-page":"831090","DOI":"10.1155\/2012\/831090","volume":"2012","author":"S Sengupta","year":"2012","unstructured":"Sengupta S, Marrinan J, Frishman C, Sampath P (2012) Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol 2012:831090. \n                    https:\/\/doi.org\/10.1155\/2012\/831090","journal-title":"Clin Dev Immunol"},{"key":"2791_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1479-5876-11-135","volume":"11","author":"L Ridolfi","year":"2013","unstructured":"Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, de Rosa F, Valmorri L, Scarpi E, Nicoletti SV, Baravelli S, Riccobon A, Ridolfi R (2013) Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med 11:135. \n                    https:\/\/doi.org\/10.1186\/1479-5876-11-135","journal-title":"J Transl Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2791-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2791-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2791-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:30:14Z","timestamp":1589700614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2791-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2791"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2791-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"19 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}